USA flag logo/image

An Official Website of the United States Government

Full Range Spectral Domain Anterior Segment OCT Scanner

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85653
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
EY018021
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOPTIGEN, INC.
633 Davis Drive Tech 9 Suite 480 Morrisville, NC 27560
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Full Range Spectral Domain Anterior Segment OCT Scanner
Agency: HHS
Contract: 1R43EY018021-01
Award Amount: $154,993.00
 

Abstract:

DESCRIPTION (provided by applicant): In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical an d applied research applications. OCT is a relatively new technology for ophthalmic imaging, which uses low-coherence interferometry to obtain cross-sectional images in living tissues with micron-scale resolution noninvasively. OCT systems based on the orig inal time-domain interferometry technology have been successfully demonstrated for human retinal and anterior segment imaging at 830nm and 1300nm wavelengths, respectively, however the slower image acquisition rate and lower signal-to-noise ratio of the ol der technology places severe constraints on the range of subjects which can be successfully imaged. In order to immobilize patients for long acquisition times, retinal and anterior segment OCT imagers commercialized to date have been built into standard ta bletop slit-lamp biomicroscope designs. The resulting systems are bulky and limit the range of potential subjects to cooperative humans who can sit upright and fixate well for several seconds. In the last few years, Fourier domain OCT (FDOCT) technology ha s emerged as a superior alternative to time-domain OCT, exhibiting improved image acquisition speed and robust system design. The increased image acquisition speed opens the possibility for the first time for ophthalmic OCT imaging with handheld probes, an d the robust design potential of FDOCT enables the implementation of truly portable systems. Bioptigen, Inc., a startup company affiliated with Duke University, has marketed state-of-the- art retinal FDOCT systems operating at 830nm wavelength using both c onventional and handheld delivery optics, and also markets a tabletop microscope-based 1300nm wavelength OCT system for small animal imaging and other pre-clinical research applications. However, due to a limitation intrinsic to FDOCT, both of these system s are limited in imaging depth to less than 4 millimeters, which is insufficient for full-depth anterior segment imaging. In this SBIR Phase I proposal, Bioptigen proposes to adapt their 1300nm OCT and handheld probe technology for high speed, handheld, fu ll-depth anterior segment imaging which will make the benefits of ophthalmic OCT imaging available to a much wider class of subjects, including bedridden and infant human patients, as well as animals of all sizes (from mouse to horse) used in biomedical an d veterinary research. In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied rese arch applications. This imaging system will be able to image the full depth of the anterior segment (gt 6mm) by developing a novel approach to complex conjugate artifact removal.

Principal Investigator:

Eric Buckland

Business Contact:


ebuckland@bioptigen.com
Small Business Information at Submission:

BIOPTIGEN, INC.
BIOPTIGEN, INC. BPX 13569 DURHAM, NC 27709

EIN/Tax ID: 156247672
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No